Conference paper

Differences among bisfosfonates - specificity of risedronate (Actonel®)

Zlatko Giljević ; Department for Endocrinology and Metabolic Diseases, Clinic for Internal Medicine, Clinical Hospital Centre Zagreb, Zagreb, Croatia

Abstract

Bisphosphonates, a gold standard in therapeutic options for the management of osteoporosis, inhibit bone resorption with relatively few side effects. As a result, they are widely used for the prevention and treatment of osteoporosis. There are clear biochemical and pharmacological differences among bisfosfonates group. Risedronate has moderate mineral binding and has a higher inhibition of a key branch-point enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway. Risedronate (Actonel®) prevents vertebral and nonvertebral fractures as early as at 6 months of treatment. Clinical trials and observational trials have proved risk reduction of vertebral and hip fractures. Patients remarkably preferred therapy with a proven antifracture efficacy over a dosage frequency.

Keywords

bisfosfonates; risedronate

Hrčak ID:

125253

URI

https://hrcak.srce.hr/125253

Publication date:

17.10.2008.

Article data in other languages: croatian

Visits: 735 *